Related Experiment Video

Updated: May 18, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

[Molecular targeted anticancer agents in the First in Human study--possibility for dosing healthy volunteers]

Ryuichi Kato1

  • 1kron099@chive.ocn.ne.jp

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|September 15, 2012
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Experiment Videos

Last Updated: May 18, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Risk Assessment of Non-Urinary Tract Recurrence After Radical Nephroureterectomy Based on CheckMate 274 Trial Eligibility: A Multicenter Retrospective Study.

International journal of urology : official journal of the Japanese Urological Association·2026

Aspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes - Prespecified Subgroup Analysis of the STOPDAPT-3 Trial.

Circulation journal : official journal of the Japanese Circulation Society·2026

Feasibility and effectiveness of distal radial access in ST-elevation myocardial infarction from a SPEEDY PCI subanalysis.

Scientific reports·2026

Structural basis for spectral red shift and UVA absorption in the microalgal water-soluble astaxanthin-binding protein AstaP-pink1.

Journal of structural biology·2026

Functional and Structural Characterization of a Novel Anti-His-tag Antibody, HisMab-1.

Journal of molecular biology·2025

Pulmonary Vein Isolation Using a Circular Multielectrode Pulsed Field Ablation Catheter via a Jugular Vein Approach.

Journal of arrhythmia·2025

[Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec® ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

[Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway®)].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

[Oxytocin regulates social familiarity-dependent mate choice in medaka].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

[Neurobiology of pair-bonded sociality in prairie voles].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

[Light stress-induced damage to intracellular membrane organelles and its preventive strategies].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

[Membrane lipids and galactose-recognizing lectin, galectin].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

EGFR kinase inhibitors from novel thiazole derivatives: synthesis, anticolon cancer, docking, and ADME studies.

Future medicinal chemistry·2026

Beyond the ceiling: A critical analysis of microRNA research in cutaneous T-cell lymphoma and a roadmap forward.

The Journal of investigative dermatology·2026

Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia.

Cancer discovery·2026

Epigenetic Repression of Type I Interferon Signaling by RUNX2 Drives Immune Checkpoint Blockade Resistance in Osteosarcoma.

Cancer research·2026

The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity.

Cancer research·2026

Targeting glutaminase (GLS) to suppress CXCL8 secretion and sensitize esophageal squamous cell carcinoma to immunotherapy.

Journal of chemotherapy (Florence, Italy)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us